Rivaroxaban

"Rivaroxaban" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Descriptor ID	D000069552
MeSH Number(s)	D02.886.778.727 D03.383.533.640.713 D03.383.903.727
Concept/Terms	Rivaroxaban Rivaroxaban 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide Xarelto Xarelto BAY 59-7939 BAY 59-7939 BAY 59 7939 BAY 597939

Below are MeSH descriptors whose meaning is more general than "Rivaroxaban".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Sulfur Compounds [D02.886]
Thiophenes [D02.886.778]
Rivaroxaban [D02.886.778.727]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Oxazines [D03.383.533]
Morpholines [D03.383.533.640]
Rivaroxaban [D03.383.533.640.713]
Thiophenes [D03.383.903]
Rivaroxaban [D03.383.903.727]

Below are MeSH descriptors whose meaning is related to "Rivaroxaban".

Below are MeSH descriptors whose meaning is more specific than "Rivaroxaban".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Rivaroxaban" by people in this website by year, and whether "Rivaroxaban" was a major or minor topic of these publications.

Bar chart showing 13 publications over 7 distinct years, with a maximum of 3 publications in 2015 and 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2012	0	1	1
2013	0	2	2
2014	0	2	2
2015	1	2	3
2018	1	0	1
2021	0	1	1
2023	0	3	3

Below are the most recent publications written about "Rivaroxaban" by people in Profiles.

Hwang YJ, Chang HY, Metkus T, Andersen KM, Singh S, Alexander GC, Mehta HB. Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study. Drug Saf. 2024 Mar; 47(3):251-260.

View in: PubMed
Huang J, Mazer CD, Boisen ML, Tibi P, Baker RA, Chu D, Moffatt-Bruce S, Shore-Lesserson L. Safety of Andexanet Alfa Use in Cardiac Surgery. J Cardiothorac Vasc Anesth. 2023 07; 37(7):1332-1334.

View in: PubMed
Lawal OD, Aronow HD, Shobayo F, Hume AL, Taveira TH, Matson KL, Zhang Y, Wen X. Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study. Circulation. 2023 03 07; 147(10):782-794.

View in: PubMed
Weiss L, Keaney J, Szklanna PB, Prendiville T, Uhrig W, Wynne K, Kelliher S, Ewins K, Comer SP, Egan K, O'Rourke E, Moran E, Petrov G, Patel A, Lennon ?, Blanco A, Kevane B, Murphy S, N? ?inle F, Maguire PB. Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures. J Thromb Haemost. 2021 10; 19(10):2583-2595.

View in: PubMed
Witte KK, Tsivgoulis G, Reynolds MR, Tsintzos SI, Eggington S, Ismyrloglou E, Lyon J, Huynh M, Egea M, de Brouwer B, Ziegler PD, Franco N, Joglekar R, Rosemas SC, Liu S, Thijs V. Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation. BMC Cardiovasc Disord. 2021 03 31; 21(1):160.

View in: PubMed
Pina LM, Dong X, Zhang L, Samtani MN, Michelson AD, Justino H, Bonnet D, Harris KC, Jefferies J, McCrindle BW, Li JS. Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study). Am Heart J. 2019 07; 213:97-104.

View in: PubMed
Alcusky M, Hume AL, Fisher M, Tjia J, Goldberg RJ, McManus DD, Lapane KL. Dabigatran Versus Rivaroxaban for Secondary Stroke Prevention in Patients with Atrial Fibrillation Rehabilitated in Skilled Nursing Facilities. Drugs Aging. 2018 12; 35(12):1089-1098.

View in: PubMed
Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, Carrier M, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassis J, Kowalski S, Lee AY, Le Gal G, Le Templier G, Li N, MacKay E, Shah V, Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. Thromb Haemost. 2017 12; 117(12):2415-2424.

View in: PubMed
Westafer LM, Carpenter CR, Milne WK. Hot Off the Press: Outpatient Anticoagulation for Venous Thromboembolism Diagnosed in the Emergency Department. Acad Emerg Med. 2015 Nov; 22(11):1355-7.

View in: PubMed
Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015 Apr 24; 350:h1857.

View in: PubMed

People

Explore

Similar Concepts

Top Journals